{"id":390759,"date":"2017-12-20T00:00:00","date_gmt":"2017-12-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0016-2017-biopharma-breast-cancer-unmet-need-us-eu-2017\/"},"modified":"2026-04-30T11:25:56","modified_gmt":"2026-04-30T11:25:56","slug":"unneon0016-2017-biopharma-breast-cancer-unmet-need-us-eu-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0016-2017-biopharma-breast-cancer-unmet-need-us-eu-2017\/","title":{"rendered":"Breast Cancer | Unmet Need | US\/EU | 2017"},"content":{"rendered":"<p>The HER2-positive breast cancer treatment paradigm has undergone considerable change in recent years and is expected to evolve further as more novel therapies enter the market. The enthusiastic adoption of\u00a0HER2-targeting\u00a0biologics, Roche\/Genentech\u2019s Perjeta (pertuzumab) and Kadcyla (T-DM1), has increased the barrier of entry for new emerging therapies. However, unmet need still exists for the treatment of advanced\/metastatic HER2-positive breast cancer. Our content examines the key drivers of prescribing and analyzes the areas of significant commercial opportunities.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>What are the treatment drivers and goals for advanced\/metastatic HER2-positive breast cancer?<\/li>\n<li>What attributes are key influencers, which have limited impact, and which are hidden opportunities?<\/li>\n<li>How do current therapies perform on key treatment drivers and goals for advanced\/metastatic HER2-positive breast cancer?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in advanced\/metastatic HER2-positive breast cancer?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to U.S. and European medical oncologists for a hypothetical new, advanced\/metastatic HER2-positive breast cancer drug?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 31 European medical oncologists\u00a0fielded in February 2017.<\/p>\n<p><strong>Key companies:<\/strong> Roche\/Genentech, Novartis<\/p>\n<p><strong>Key drugs:<\/strong> Perjeta, Kadcyla, Tykerb\/Tyverb<\/p>\n","protected":false},"template":"","class_list":["post-390759","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-breast-cancer","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390759","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390759\/revisions"}],"predecessor-version":[{"id":393883,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390759\/revisions\/393883"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390759"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}